Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

Status:	Active, not recruiting
Conditions:	Neurology, Multiple Sclerosis
Therapuetic Areas:	Neurology, Other
Healthy:	No
Age Range:	18 - 55
Updated:	1/25/2019
Start Date:	May 12, 2010
End Date:	December 15, 2021

Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis

This study is an extension to the study AC-058B201 and will investigate the long-term safety,
tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple
sclerosis.

Inclusion Criteria:

1. Patients who completed study treatment at their regular Week 24 (End of treatment)
visit within the core study AC-058B201.

2. Signed informed consent for participating in the extension study.

Exclusion Criteria:

1. Any clinically relevant medical or surgical condition, which, in the opinion of the
investigator, would put the patient at risk by participating in the extension study.

We found this trial at

sites

Clinical Investigative Site 3112

Burlington, Vermont 05401

from

Burlington, VT